Alpha-1 Antitrypsin Deficiency Treatment Market Dynamics, Global Insights, Development Analysis, Growth Values and Industry Forecast to 2025
Alpha-1
Antitrypsin Deficiency Treatment Market Overview:
Registering
a CAGR of 10.50%, the global Alpha-1 Antitrypsin Deficiency
Treatment Market is expected to grow from USD 1,464.1 million
in 2018 to USD 2,914.7 million by 2025.
As of
July 2019, 3.4 million people are affected by alpha-1 antitrypsin deficiency
worldwide. The disorder is found to affect populations in all the regions of
the world.
The
market is dominated by numerous established players. The key players are
involved in product launches, strategic collaborations, and awareness programs
to strengthen their market positions. For instance, in November 2018, Grifols
S. A. launched the AlfaCare therapy program for training and counseling of
patients diagnosed with alpha-1 antitrypsin deficiency.
Browse
Full Report Details and TOC Exclusively @
Alpha-1 Antitrypsin Deficiency Treatment Market-Key Players
·
Kamada Pharmaceuticals
·
CSL Behring LLC
·
Grifols
·
Takeda Pharmaceutical Company Limited
·
GlaxoSmithKline plc
·
Boehringer Ingelheim GmbH
·
AstraZeneca
·
Vectura Group plc
·
Pfizer Inc
·
Mylan Inc
.
Alpha-1
Antitrypsin Deficiency Treatment Market-Segmentation
By Drugs:
·
Alpha-1 Proteinase Inhibitor: The segment is
expected to hold the largest market share as it is the only treatment for AATD,
which protects the patient from more lung damage.
·
Bronchodilators: These are used for the treatment
of respiratory disorders associated with AATD.
·
Steroids: These are used specifically for the
treatment of chronic obstructive pulmonary
disease, which affects the patient along with AATD.
·
Others: Other treatment options include
antibiotics for infections and jaundice associated with AATD and oxygen
therapy.
By
Route of Administration:
·
Oral: The segment is expected to hold the
largest market share.
·
Intravenous: The segment is expected to grow
at the fastest CAGR.
·
Inhalation: This route of administration is
used specifically for the administration of corticosteroids for treating
breathing disorders.
·
Others: Subcutaneous and intramuscular routes
of administration.
By Distribution
Channel:
·
Hospital Pharmacy: The rise in the number of
hospitals is likely to be responsible for the largest market size.
·
Retail Pharmacy: These fulfill the
requirement of drugs that are needed for treatment at home.
·
Online Stores: The fastest-growing segment
owing to increase in number of online pharmacies.
By
Region
·
Americas: The
region holds the largest share of the market. The market in the Americas has
further been branched into North America and Latin America, with the North
American market divided into the US and Canada.
·
Europe: The
European alpha-1 antitrypsin deficiency treatment market has been classified as
Western Europe and Eastern Europe. The Western European market has further been
categorized as Germany, France, the UK, Italy, Spain, and the rest of Western
Europe.
·
Asia-Pacific: The
market in Asia-Pacific has been segmented into Japan, China, India, South
Korea, Australia, and the rest of Asia-Pacific. The Asia-Pacific alpha-1
antitrypsin deficiency treatment market is projected to be the fastest-growing
during the forecast period.
·
Middle East & Africa: The
market in the Middle East & Africa has been divided into the Middle East
and Africa.
About Market
Research Future:
At Market Research Future (MRFR),
we enable our customers to unravel the complexity of various industries through
our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw
Research Reports (3R), Continuous-Feed Research (CFR), and Market Research
& Consulting Services.
Contact:
Market
Research Future
Office No.
528, Amanora Chambers
Magarpatta
Road, Hadapsar,
Pune - 411028
Maharashtra,
India
+1 646 845
9312
Email: sales@marketresearchfuture.com
Comments
Post a Comment